The Forbeck Foundation, with its roots in neuroblastoma, has been a sponsor of the ANR Conference for many years.
Held every other year and dedicated entirely to neuroblastoma, this year’s conference, titled, Building Bridges for Neuroblastoma Research, will be chaired by the Forbeck Foundation’s Scientific Advisory Board member, Kate Matthay, M.D., UCSF School of Medicine.
ANR convenes an international group with many different research disciplines in the science and clinical care for neuroblastoma. Conference participants will have the opportunity to present their work and learn about each other’s advances in the science of neuroblastoma and the care of persons and families affected. There will be presentations, workshops, exhibitor demonstrations and sessions with international experts.
This year, on May 9, we will be sponsoring a workshop titled, Immunotherapy Beyond GD2 for the Oncologist: Role of T cells, NK cells, PD1 and the Microenvironment. The workshop will examine the role of the patient’s own immune cells in fighting cancer and how those cells can be influenced to make them more effective in eliminating cancer cells. Thus, cells can be modified in the laboratory to make them more tumor-targeted, or special antibodies against the tumor can be synthesized that will then work together with the patient’s immune system to kill the cancer.
The workshop may include optimal preclinical models for immunotherapy, targeting the microenvironment, combination immunotherapies, cellular therapies with NK cells, CAR-T cells, vaccines, ongoing clinical trials, and toxicities. See below for details:
Exploring T Cell Mediated Anti-Tumor Immune Responses in Neuroblastoma
John Maris, M.D. (Children’s Hospital of Philadelphia)
Bispecific Antibodies – Protein Engineering for Cancer Cure
Nai-Kong Cheung, M.D., Ph.D. (Memorial Sloan Kettering Cancer Center, NY)
Checkpoint Inhibition in Cancer
Ira Mellman, Ph.D. (Genentech Inc.)
CAR T Cells for Neuroblastoma: Progress and Challenges
Crystal Mackall, M.D. (Stanford University, Stanford CA)
1RG-CART, A CRUK-Sponsored Phase I Trial to Evaluate A Novel Chimeric Antigen Receptor Transduced Autologous T Cells in Children with Neuroblastoma
John Anderson, Ph.D. (UCL Great Ormond Street Institute of Child Health)
Immunotherapy has been an important topic to the Foundation for our 30+ year history, and we are proud to be sponsoring this workshop at ANR. Two of our past scholars, Sharon Diskin, Ph.D., Children’s Hospital of Philadelphia and Annette Künkele, M.D., University Hospital Berlin, will be representing the organization. We look forward to presenting their reports following the meeting.
To read more about this year’s ANR Conference, visit anr2018.org